Skip to main content

Predictors for Use of Sentinel Node Biopsy and the Association with Improved Survival in Melanoma Patients Who Have Nodal Staging

Annals of Surgical Oncology volume 25, pages 903–911 (2018)Cite this article

Abstract

Background

It is unknown how many patients with localized melanoma undergo sentinel lymph node biopsy (SLNB) or if there is a therapeutic effect from performing nodal staging. We evaluated predictors for SLNB use and assessed if there was an association with improved survival in melanoma patients who had SLNB.

Methods

The Surveillance, Epidemiology, and End Results database was queried for clinically node-negative melanoma cases ≥ 0.75 mm in thickness treated from 2010 to 2012. Clinicopathologic factors were correlated with SLNB use, overall survival (OS), and melanoma-specific survival (MSS).

Results

Overall, 13,703 cases were included. SLNB was performed in 1479 of 3439 thin cases (43.0%), 5810 of 8522 intermediate-thickness cases (68.2%), and 916 of 1742 thick cases (52.6%). On multivariable analysis, age ≥ 70 years, thickness < 1 or > 4 mm, head/neck or trunk tumor location, being unmarried, African American race, and residing in a county with a lower level of education were significantly associated with a lower likelihood of performing SLNB (p < 0.05). Patients with intermediate-thickness or thick melanoma who had a SLNB had significantly improved OS and MSS compared with patients who did not have a SLNB (p < 0.05). On multivariable analysis, SLNB use significantly predicted for improved OS and MSS (p < 0.01).

Conclusions

Only 68.2% of intermediate-thickness and 52.6% of thick melanomas are treated with SLNB. Age, thickness, tumor location, race, marital status, and socioeconomic factors appear to influence the performance of SLNB. This data becomes more relevant with the finding that SLNB use is potentially associated with improved survival.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–399.

    CAS  Article  PubMed  Google Scholar 

  2. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3):976–983.

    CAS  Article  PubMed  Google Scholar 

  4. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–1317.

    CAS  Article  PubMed  Google Scholar 

  5. Bello DM, Han G, Jackson L, et al. The prognostic significance of sentinel lymph node status for patients with thick melanoma. Ann Surg Oncol. 2016;23 Suppl 5:938–945.

    Article  PubMed  Google Scholar 

  6. Han D, Zager JS, Shyr Y, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31(35):4387–4393.

    Article  PubMed  Google Scholar 

  7. Han D, Yu D, Zhao X, et al. Sentinel node biopsy is indicated for thin melanomas >/=0.76 mm. Ann Surg Oncol. 2012;19(11):3335-3342.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Rubinstein JC, Han G, Jackson L, et al. Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. Cancer Med. 2016;5(10):2832–2840.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Yamamoto M, Fisher KJ, Wong JY, et al. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer. 2015;121(10):1628–1636.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Ribero S, Osella-Abate S, Sanlorenzo M, et al. Sentinel lymph node biopsy in thick-melanoma patients (N = 350): what is its prognostic role? Ann Surg Oncol. 2015;22(6):1967–1973.

    CAS  Article  PubMed  Google Scholar 

  11. Mozzillo N, Pennacchioli E, Gandini S, et al. Sentinel node biopsy in thin and thick melanoma. Ann Surg Oncol. 2013;20(8):2780–2786.

    Article  PubMed  Google Scholar 

  12. CR, Bowen AL, Martin RC, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg. 2010;145(7):622–627.

    Article  PubMed  Google Scholar 

  13. Gajdos C, Griffith KA, Wong SL, et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer. 2009;115(24):5752–5760.

    Article  PubMed  Google Scholar 

  14. Maurichi A, Miceli R, Camerini T, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol. 2014;32(23):2479–2485.

    Article  PubMed  Google Scholar 

  15. Murali R, Scolyer RA, Thompson JF. Can we better identify thin cutaneous melanomas that are likely to metastasize and cause death? Ann Surg Oncol. 2012;19(11):3310–3312.

    Article  PubMed  Google Scholar 

  16. Venna SS, Thummala S, Nosrati M, et al. Analysis of sentinel lymph node positivity in patients with thin primary melanoma. J Am Acad Dermatol. 2013;68(4):560–567.

    Article  PubMed  Google Scholar 

  17. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American society of clinical oncology and Society of surgical oncology joint clinical practice guideline. J Clin Oncol. 2012;30(23):2912–2918.

    Article  PubMed  Google Scholar 

  18. Coit D, Thompson, JA. NCCN Clinical Pratice Guidelines in Oncology: Melanoma, Ver. 1.2017. National Comprehensive Cancer Network; 10 Nov 2016.

  19. Bilimoria KY, Balch CM, Wayne JD, et al. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol. 2009;27(11):1857–1863.

    Article  PubMed  Google Scholar 

  20. Erickson JL, Velasco JM, Hieken TJ. Compliance with melanoma treatment guidelines in a community teaching hospital: time trends and other variables. Ann Surg Oncol. 2008;15(4):1211–1217.

    Article  PubMed  Google Scholar 

  21. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 9, Mar 2016 (1973–2014) < Katrina Population Adjustment > , Linked to County Attributes—Total U.S., 1969–2014 Counties. Based on Nov 2015 Submission. National Cancer Institute; 2016.

  22. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005;23(21):4735–4741.

    Article  PubMed  Google Scholar 

  23. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Sabel MS, Kozminski D, Griffith K, Chang AE, Johnson TM, Wong S. Sentinel lymph node biopsy use among melanoma patients 75 years of age and older. Ann Surg Oncol. 2015;22(7):2112–2119.

    Article  PubMed  Google Scholar 

  25. Moran DE, Smith MJ, O’Sullivan MJ, et al. Sentinel lymph node biopsy in elderly irish patients with malignant melanoma. Ir Med J. 2007;100(4):422–424.

    CAS  PubMed  Google Scholar 

  26. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29(16):2199–2205.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45(12):3012–3017.

    CAS  Article  PubMed  Google Scholar 

  28. Robards J, Evandrou M, Falkingham J, Vlachantoni A. Marital status, health and mortality. Maturitas. 2012;73(4):295–299.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hu YR, Goldman N. Mortality differentials by marital status: an international comparison. Demography. 1990;27(2):233–250.

    CAS  Article  PubMed  Google Scholar 

  30. McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg. 2006;32(4):493–504.

    CAS  PubMed  Google Scholar 

  31. Leong SP, Achtem TA, Habib FA, et al. Discordancy between clinical predictions vs lymphoscintigraphic and intraoperative mapping of sentinel lymph node drainage of primary melanoma. Arch Dermatol. 1999;135(12):1472–1476.

    CAS  Article  PubMed  Google Scholar 

  32. Patel SG, Coit DG, Shaha AR, et al. Sentinel lymph node biopsy for cutaneous head and neck melanomas. Arch Otolaryngol Head Neck Surg. 2002;128(3):285–291.

    Article  PubMed  Google Scholar 

  33. Kasprzak JM, Xu YG. Diagnosis and management of lentigo maligna: a review. Drugs Context. 2015;4:212281.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Koh HK, Michalik E, Sober AJ, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol. 1984;2(9):994–1001.

    CAS  Article  PubMed  Google Scholar 

  35. Mahendraraj K, Sidhu K, Lau CS, McRoy GJ, Chamberlain RS, Smith FO. Malignant melanoma in African–Americans: a population-based clinical outcomes study involving 1106 African–American patients from the surveillance, epidemiology, and end result (SEER) Database (1988–2011). Medicine (Baltimore). 2017;96(15):e6258.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgement

The authors would like to thank Daniel C. Thomas for his support of this article.

Disclosure

None.

Author information

Affiliations

  1. Section of Surgical Oncology, Department of Surgery, Yale School of Medicine, New Haven, CT, USA

    Timothy D. Murtha MD, MHS & Dale Han MD, FACS

  2. Department of Epidemiology and Biostatistics, School of Public Health, Texas A&M University, College Station, TX, USA

    Gang Han PhD

Authors
  1. Timothy D. Murtha MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gang Han PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dale Han MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dale Han MD, FACS.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Murtha, T.D., Han, G. & Han, D. Predictors for Use of Sentinel Node Biopsy and the Association with Improved Survival in Melanoma Patients Who Have Nodal Staging. Ann Surg Oncol 25, 903–911 (2018). https://doi.org/10.1245/s10434-018-6348-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6348-2

Keywords

  • Sentinel Lymph Node Biopsy (SLNB)
  • Melanoma Patients
  • Thick Melanomas
  • Melanoma-specific Survival (MSS)
  • Localized Melanoma